Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b ...

Things are going from bad to worse for the pharmaceutical giant.

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Though the stock looks attractive relative to the industry, a discounted valuation like Pfizer's does not automatically mean one should buy a stock. To make an informed decision, whether this ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer (PFE) CEO Albert Bourla is bullish about the company's near-term outlook after a flubbed attack campaign from activist investor Starboard Value earlier this month. "We have launched an ...

Chicago, IL – October 6, 2025 – Zacks Value Trader is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec. Every week, Tracey will be joined by guests to discuss the hottest investing ...

Pfizer PFE reported stronger third-quarter results than we anticipated, largely due to significantly higher sales of covid-19 treatment Paxlovid, which also drove management to increase its top- and ...

Pfizer (PFE) stock drops 3% as CFO Dave Denton reveals August exit. Cecile Guegan appointed interim CFO while company ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...